Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Division of Biomedical System Engineering, Graduate School of Science and Engineering for Education, University of Toyama, Toyama, Japan; Department of Chemistry and Institute of BioPhysio Sensor Technology (IBST), Pusan National University, Busan, 46241, South Korea; Department of Chemistry, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Road, Riyadh, 11533, Saudi Arabia; Toyama Nanotechnology Manufacturing Cluster, Toyama, Japan.
J Pharm Biomed Anal. 2019 Feb 5;164:93-103. doi: 10.1016/j.jpba.2018.10.017. Epub 2018 Oct 9.
Lung cancer is undoubtedly one of the most serious health issues of the 21 st century. It is the second leading cause of cancer-related deaths in both men and women worldwide, accounting for about 1.5 million deaths annually. Despite advances in the treatment of lung cancer with new pharmaceutical products and technological improvements, morbidity and mortality rates remains a significant challenge for the cancer biologists and oncologists. The vast majority of lung cancer patients present with advanced-stage of pathological process that ultimately leads to poor prognosis and a five-year survival rate less than 20%. Early and accurate screening and analysis using cost-effective means are urgently needed to effectively diagnose the disease, improve the survival rate or to reduce mortality and morbidity associated with lung cancer patients. Thus, the only hope for early recognition of risk factors and timely diagnosis and treatment of lung cancer is biosensors technology. Novel biosensing based diagnostics approaches for predicting metastatic risks are likely to have significant therapeutic and clinical impact in the near future. This article systematically provides a brief overview of various biosensing platforms for identification of lung cancer disease biomarkers, with a specific focus on recent advancements in electrochemical and optical biosensors, analytical performances of different biosensors, challenges and further research opportunities for routine clinical analysis.
肺癌无疑是 21 世纪最严重的健康问题之一。它是全世界男性和女性癌症相关死亡的第二大主要原因，每年导致约 150 万人死亡。尽管在治疗肺癌方面取得了新的药物产品和技术进步，但发病率和死亡率仍然是癌症生物学家和肿瘤学家面临的重大挑战。绝大多数肺癌患者在病理过程的晚期出现，最终导致预后不良，五年生存率低于 20%。迫切需要使用具有成本效益的手段进行早期和准确的筛选和分析，以有效诊断疾病，提高生存率或降低与肺癌患者相关的死亡率和发病率。因此，早期识别风险因素以及及时诊断和治疗肺癌的唯一希望是生物传感器技术。基于新型生物传感器的预测转移风险的诊断方法在不久的将来可能会对治疗和临床产生重大影响。本文系统地概述了用于识别肺癌疾病生物标志物的各种生物传感平台，特别关注电化学和光学生物传感器的最新进展、不同生物传感器的分析性能、常规临床分析的挑战和进一步的研究机会。
